Furthermore, given that KRAS mutations are widely reported in several cancer types, exploring the role of CREPT in regulating mutation-induced activation of MAPK signaling in these other cancers remains an intriguing avenue for future research. The gene discussed is RPRD1B; the disease is cancer.